218 related articles for article (PubMed ID: 7679336)
21. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers.
Seamonds B; Yang N; Anderson K; Whitaker B; Shaw LM; Bollinger JR
Urology; 1986 Dec; 28(6):472-9. PubMed ID: 2431533
[TBL] [Abstract][Full Text] [Related]
23. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen: update 1997.
Chan DW; Sokoll LJ
J Int Fed Clin Chem; 1997 Sep; 9(3):120-5. PubMed ID: 10174623
[TBL] [Abstract][Full Text] [Related]
25. Tumour markers in prostatic cancer.
Cooper EH
Scand J Clin Lab Invest Suppl; 1991; 206():42-51. PubMed ID: 1719610
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
27. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
28. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project.
Kane RA; Littrup PJ; Babaian R; Drago JR; Lee F; Chesley A; Murphy GP; Mettlin C
Cancer; 1992 Mar; 69(5):1201-7. PubMed ID: 1371234
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.
Chan TY; Mikolajczyk SD; Lecksell K; Shue MJ; Rittenhouse HG; Partin AW; Epstein JI
Urology; 2003 Jul; 62(1):177-81. PubMed ID: 12837462
[TBL] [Abstract][Full Text] [Related]
31. A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland.
van Dieijen-Visser MP; Delaere KP; Gijzen AH; Brombacher PJ
Clin Chim Acta; 1988 May; 174(2):131-40. PubMed ID: 2454767
[TBL] [Abstract][Full Text] [Related]
32. How important are the prostate-specific antigen assays?
Vessella RL
Contemp Intern Med; 1994 Feb; 6(2):76-89. PubMed ID: 10146682
[No Abstract] [Full Text] [Related]
33. Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate.
Dupont A; Cusan L; Gomez JL; Thibeault MM; Tremblay M; Labrie F
J Urol; 1991 Oct; 146(4):1064-7; discussion 1067-8. PubMed ID: 1716697
[TBL] [Abstract][Full Text] [Related]
34. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
35. A brief review of ultrasensitive prostate-specific antigen assays for the evaluation of patients after radical prostatectomy.
Takayama TK; Vessella RL; Lange PH
World J Urol; 1993; 11(4):192-5. PubMed ID: 7508782
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
37. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening SA; Sinha P
Clin Chem; 2000 Jan; 46(1):47-54. PubMed ID: 10620571
[TBL] [Abstract][Full Text] [Related]
38. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
Benson MC; Whang IS; Pantuck A; Ring K; Kaplan SA; Olsson CA; Cooner WH
J Urol; 1992 Mar; 147(3 Pt 2):815-6. PubMed ID: 1371554
[TBL] [Abstract][Full Text] [Related]
39. [Prostate-specific antigen in prostatic pathology].
Teillac P; Peyret C; Leroy M; Najean Y; Le Duc A
Ann Urol (Paris); 1988; 22(3):193-6. PubMed ID: 2456712
[TBL] [Abstract][Full Text] [Related]
40. The clinical usefulness of prostate specific antigen: update 1994.
Partin AW; Oesterling JE
J Urol; 1994 Nov; 152(5 Pt 1):1358-68. PubMed ID: 7523702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
